Evaluation of abiraterone acetate post-docetaxel in the Belgian compassionate use program.

e16057 Background: To assess efficacy and safety of abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who started treatment during the AA compassionate use program (January 2011 - July 2012). Methods: We retrospectively analyzed records from 368 patients from 23 different Belgian hospitals. All patients had mCRPC, received prior chemotherapy and started AA at the standard dose of 1000mg per day with 10mg prednisone or equivalent. Principal outcomes measured were prostate-specific antigen (PSA) response (defined as a decrease ≥ 50%), time to PSA progression (defined as an increase > 50% over PSA nadir in case of PSA response or > 25% in the absence of PSA response), time to radiographic progression (according to Response Evaluation Criteria In Solid Tumors 1.1 criteria), overall and cancer-specific survival and occurrence of adverse events (according to Common Terminology Criteria for Adverse Events v4.03). Kaplan-Meier stati...